Eli Lilly and Company

Artificial intelligence-enabled drug discovery and development is one of the hottest topics in the biopharmaceutical industry, capturing the imaginations of investors, entrepreneurs and veterans alike

Patients with early Alzheimer’s disease, caregivers and doctors who may have been reluctant to try Eli Lilly’s Kisunla (donanemab) due to the risk of amyloid-related imaging abnormalities (ARIA) with

Frontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,

The outlook for biopharmaceutical company financings has grown increasingly grim in 2025 as drug developer valuations remain challenged by various macroeconomic and industry-specific concerns. New dat